BPC-157 vs KPV
Side-by-side comparison of BPC-157, KPV — mechanism, dosing, half-life, side effects, and research status.
| Attribute | BPC-157 Body Protection Compound-157 Recovery | KPV KPV (Lys-Pro-Val) — Alpha-MSH Tripeptide Recovery |
|---|---|---|
| Basics | ||
| Molecular type | Gastric Pentadecapeptide | Alpha-MSH C-terminal Tripeptide |
| Amino acids | 15 | 3 |
| Molecular weight | 1,419.5 Da | 355.4 Da |
| Half-life | ~4 hrs (SC) | Short (hours) |
| Route(s) | Subcutaneous, Intramuscular, Oral (research only) | Subcutaneous, Oral (GI conditions), Topical |
| Mechanism & Research | ||
| Primary mechanism | BPC-157 exerts its primary effects through upregulation of the nitric oxide (NO) signalling pathway. By promoting NO synthase activity, it drives vasodilation and angiogenesis at injury sites, accelerating the delivery o… | KPV binds melanocortin receptors (MC1R and MC3R) expressed on immune cells, epithelial cells, and neurons. Receptor activation suppresses NF-κB-mediated pro-inflammatory cytokine production (TNF-α, IL-6, IL-8) and drives… |
| Research status | Research Compound | Research Compound |
| Evidence summary | The majority of BPC-157 research is preclinical (animal and in vitro). No large-scale randomised controlled trials in humans have been published as of 2026. The FDA's 2024 assessment noted insufficient human safety and e… | KPV has robust preclinical data for inflammatory bowel conditions (Crohn's disease, ulcerative colitis models) and wound healing. Oral nanoparticle formulations have been developed to improve colonic delivery. |
| Protocol & Dosing | ||
| Typical dose | 200–500 mcg per injection | 500 mcg–2 mg/day (SC); variable oral dosing |
| Frequency | Once or twice daily | Once or twice daily |
| Duration | 4–12 weeks | 4–8 weeks |
| Timing | Near injury site when possible | Any time; pre-meals for GI applications |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Prohibited (WADA S0) | Not Prohibited |
| Deeper reading | ||
| Related peptides | TB-500, GHK-Cu, KPV, Pentadeca Arginate | BPC-157, LL-37, TB-500 |
| Full profile | Read full BPC-157 profile → | Read full KPV profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.